Expression vector of human interferon induced transmembrane protein 3 (IFITM3).
Clone info. | Expression vector of human interferon induced transmembrane protein 3 (IFITM3), tagged with 3xFLAG at C-termonus. |
---|---|
Comment | Human IFITM3 was cloned using cDNA from HeLa cell. Expression was confirmed by the depositor with western blotting. |
Vector backbone | p3xFLAGCMV14 (plasmid) |
Size of vector backbone | 6.3 kb |
Selectable markers | Amp^r (E. coli), Neo^r (mammalian cells). |
Gene/insert name | human IFITM3 cDNA |
Depositor|Developer | Nishijima, Kenichi | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Approval form by depositor [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested (Okuzaki, Y et al. Biosci. Biotechnol. Biochem. 81(5): 914-921, 2017). RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. |
Remarks | ((Additional form)) Approval Form(FormD) Please obtain written approval of the depositor. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 寄託者による提供承諾書 [Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 1.利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。2. 利用者は、研究成果の公表にあたって開発者の指定する文献を引用する(Okuzaki, Y et al. Biosci. Biotechnol. Biochem. 81(5): 914-921, 2017)。3. 寄託者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。4. 営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。 |
備考 | 【追加提供依頼書】承諾書(FormD) 寄託者の書面による提供承諾が必要です。 |
Catalog # | Resource name | Shipping form | Fee (non-profit org.) |
---|---|---|---|
RDB15717 | p3xFLAGCMV_hIFITM3 | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The p3xFLAGCMV_hIFITM3 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15717). |
Reference section:
Okuzaki, Y., Kidani, S., Kaneoka, H., Iijima, S., Nishijima, K., Characterization of chicken interferon-inducible transmembrane protein-10. Biosci. Biotechnol. Biochem. 81 (5): 914-921 (2017). PMID 28084173. [link to RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB15717_A7Lip1.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: CMV-Forward Sequence file: RDB15717_A7Lia.seq ![]() |
---|
>D05099A2_A7Li_1_CMV-Forward_D01_10_ABI24.ab1 1 CTATATTACC CCGCCCGTTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA 61 TAAGCAGAGC TCGTTTAGTG AACCGTCAGA ATTAAGCTTG CGGCCGCGAA TTCACCATGA 121 ATCACACTGT CCAAACCTTC TTCTCTCCTG TCAACAGTGG CCAGCCCCCC AACTATGAGA 181 TGCTCAAGGA GGAGCACGAG GTGGCTGTGC TGGGGGCGCC CCACAACCCT GCTCCCCCGA 241 CGTCCACCGT GATCCACATC CGCAGCGAGA CCTCCGTGCC CGACCATGTC GTCTGGTCCC 301 TGTTCAACAC CCTCTTCATG AACCCCTGCT GCCTGGGCTT CATAGCATTC GCCTACTCCG 361 TGAAGTCTAG GGACAGGAAG ATGGTTGGCG ACGTGACCGG GGCCCAGGCC TATGCCTCCA 421 CCGCCAAGTG CCTGAACATC TGGGCCCTGA TTCTGGGCAT CCTCATGACC ATTCTGCTCA 481 TCGTCATCCC AGTGCTGATC TTCCAGGCCT ATGGAGGATC CCGGGCTGAC TACAAAGACC 541 ATGACGGTGA TTATAAAGAT CATGACATCG ACTACAAGGA TGACGATGAC AAGTAGTGAT 601 CCCGGGTGGC ATCCCTGTGA CCCCTCCCCA GTGCCTCTCC TGGCCCTGGA AGTTGCCACT 661 CCAGTGCCCA CCAGCCTTGT CCTAATAAAA TTAAGTTGCA TCATTTTGTC TGACTAGGTG 721 TCCTTCTATA ATATTATGGG GTGGAGGGGG GTGGTATGGA GCAAGGG // |
Primer: SV40pro_F Sequence file: RDB15717_A7Lib.seq ![]() |
>D05099A2_A7Li_1_SV40pro-F_F01_16_ABI24.ab1 1 CCTTTGGGCG TAGGCTTTCA GAGTAGTGAG GAGGCTTTTT TGGAGGAATT GATCAGCTTG 61 GGATCTGATC AAGAGACAGG ATGAGGATCG TTTCGCATGA TTGAACAAGA TGGATTGCAC 121 GCAGGTTCTC CGGCCGCTTG GGTGGAGAGG CTATTCGGCT ATGACTGGGC ACAACAGACA 181 ATCGGCTGCT CTGATGCCGC CGTGTTCCGG CTGTCAGCGC AGGGGCGCCC GGTTCTTTTT 241 GTCAAGACCG ACCTGTCCGG TGCCCTGAAT GAACTGCAGG ACGAGGCAGC GCGGCTATCG 301 TGGCTGGCCA CGACGGGCGT TCCTTGCGCA GCTGTGCTCG ACGTTGTCAC TGAAGCGGGA 361 AGGGACTGGC TGCTATTGGG CGAAGTGCCG GGGCAGGATC TCCTGTCATC TCACCTTGCT 421 CCTGCCGAGA AAGTATCCAT CATGGCTGAT GCAATGCGGC GGCTGCATAC GCTTGATCCG 481 GCTACCTGCC CATTCGACCA CCAAGCGAAA CATCGCATCG AGCGAGCACG TACTCGGATG 541 GAAGCCGGTC TTGTCGATCA GGATGATCTG GACGAAGAGC ATCAGGGGCT CGCGCCAGCC 601 GAACTGTTCG CCAGGCTCAA GGCGCGCATG CCCGACGGCG AGGATCTCGT CGTGACCCAT 661 GGCGATGCCT GCTTGCCGAA TATCATGGTG GAAAATGGCC GCTTTTCTGG ATTCATCGAC 721 TGTGGCCGGC TGGGTGTGGC GGACCGCTAT CAGGACATAG CGTTGGCTAC CCGTGATATT 781 GCTGAAGAGC TTGGCGGCGA ATGGGCTGAC CGCTTCCTCG TGCTTTACGG TATCGCCGCT 841 CCCGATTCGC AGCGCATCGC CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT 901 CTGGGGTTCG AAATGACCGA CCAAGCGACG CCCAACCTGC CATCACGAGA TTTCGGATTC 961 CACCGCCCGC CTTTCTATGA AAGGTTGGGC TTCGGGAATC GTTTTCCCGG GACGCCGGGC 1021 TGGAATGATC CTTCCAGCGC GGGGATCTCA TGCTGGAAGT TCTTTCGCCC CACCCCCGGC 1081 TCGAATCCCC CTCGCGAATT GGGATCAGCC TGCCTGCCCT GGAGGCTGGA ACGAACCCTT 1141 CTGCCCGGA // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
original | Okuzaki, Y., Characterization of chicken interferon-inducible transmembrane protein-10. Biosci. Biotechnol. Biochem. 81 (5): 914-921 (2017). PMID 28084173. [link to RRC of NBRP] |
---|
Featured content